FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid TumorsLeigh Marcus, Steven J. Lemery, Reena Philip et al.|Clinical Cancer Research|2021Cited by 567
FDA Approval Summary: Dabrafenib in Combination with Trametinib for <i>BRAF</i>V600E Mutation–Positive Low-Grade GliomaMichael I. Barbato, Nicole Drezner, Jeannette Nashed et al.|Clinical Cancer Research|2023Cited by 70
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for childrenAndrew D.J. Pearson, Gilles Vassal, Kimberly Stegmaier et al.|European Journal of Cancer|2020Cited by 25